Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 16:34 ET | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
January 08, 2026 16:05 ET | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
January 08, 2026 16:05 ET | Source: ClinNEXUS, Inc.

ClinNEXUS Launches New Corporate Rebranding to Kick Off Attendance During Week of J.P. Morgan Healthcare Conference

-Updated logo and website better reflect patient-centric focus and accessibility as well as new inflection point for company- -ClinNEXUS management will be in attendance during “JPM Week” hosting...
January 08, 2026 16:05 ET | Source: Tvardi Therapeutics

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...
January 08, 2026 16:01 ET | Source: Ascendis Pharma

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the...
January 08, 2026 16:01 ET | Source: Senseonics Holdings, Inc.

Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of...
January 08, 2026 14:47 ET | Source: Syneos Health, Inc.

Syneos Health Appoints Simon Bartle as Chief Human Resources Officer

MORRISVILLE, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Syneos Health, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Simon Bartle as Chief...
January 08, 2026 12:08 ET | Source: Equity Insider

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with...
January 08, 2026 12:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent,...
January 08, 2026 11:00 ET | Source: TRIMEDX

TRIMEDX strengthens TRIMEDX-AIQ™ with agentic AI capital planning and inventory optimization capabilities

Indianapolis, Indiana, Jan. 08, 2026 (GLOBE NEWSWIRE) -- TRIMEDX today announced the addition of agentic AI capital planning and inventory optimization capabilities to TRIMEDX-AIQ™, its AI-native...